Disc Medicine Q3 net loss $14.1M; bitopertin Phase 2 enrollment complete

Disc Medicine, Inc.

2023-Q3 EPS reported -$2.45

Cash $370.5M as of Sep 30, 2023; expected to fund operations into 2026.
Completed enrollment for BEACON (open-label) and AURORA (placebo-controlled) Phase 2 trials of bitopertin in EPP/XLP.
Updated BEACON data including pivotal endpoint (cumulative time in sunlight) to be presented at ASH 2023.
Initiated Phase 1 trial of DISC-3405 for PV; received FDA fast track designation.
R&D expenses $14.4M (up from $7.9M YoY) driven by portfolio progression and headcount.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Disc Medicine, Inc. reported third quarter ended September 30, 2023 results: net income Net loss was $14.1 million.

Period: third quarter ended September 30, 2023
Net income: Net loss was $14.1 million
Result: reported results

Exact text from the filing

• Net Loss: Net loss was $14.1 million for the quarter ended September 30, 2023, as compared to

View on SEC.gov

Browse all earnings releases →

Disc Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-274094

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.